The Phenotyping Core will provide ORDRCC investigators with access to advanced high-content, cutting-edge biomolecular phenotyping services and datasets spanning genetic, genomic, proteomic, and functional cellular bioresponses on clinical samples available through the Clinical Characterization and Biorepository Core (CCBC) or from other ORDRCC Investigator projects. The tight integration of the Phenotyping Core and the CCBC within the ORDRCC enables both the efficient performance of phenotype characterizations and correlation of the clinical characteristics with molecular or cellular phenotypes on specific clinical samples. Consolidation of the range of technologies required for the complete characterization of a molecular or cellular phenotype into a single Core allows the Core to better assist all ORDRCC investigators in the efficient planning/design, execution and data analysis as dictated by their individual project needs. The Core is able to provide experience in performing research using clinical specimens, the necessary technical expertise in a wide range of molecular and bioassays, access to equipment and resources enabling cutting-edge approaches to address research questions, quality control assessment of the data collected and data processing suitable for higher end statistical modeling of phenotype/clinical associations. Therefore, the goals of the Phenotyping Core can be summarized as follows: Goal 1: Offer expert consulting for experimental project design, cost analysis, implementation planning and project management for ORDRCC investigators. Goal 2: Provide access to advanced technology, centralized equipment and experienced personnel for high throughput/high content experimental phenotype characterization and biomarker assays in genetic, genomic, proteomic, immune phenotype and immune functional domains. Goal 3: Supply guidance on data quality control, processing of raw data, and preparation of data sets for more extensive statistical modeling. Goal 4: Assess and develop new cutting edge technologies for phenotype characterization.
This Phenotyping Core provides ORDRCC investigators access to the technical expertise and resources to perform genetic, genomic, proteomic and cellular phenotype/function biomarker analyses required to develop a world class rheumatic disease focused clinical-translational research career.
|St Clair, E William; Baer, Alan N; Wei, Chungwen et al. (2018) Clinical Efficacy and Safety of Baminercept, a Lymphotoxin ? Receptor Fusion Protein, in Primary Sjögren's Syndrome: Results From a Phase II Randomized, Double-Blind, Placebo-Controlled Trial. Arthritis Rheumatol 70:1470-1480|
|Martínez-Bueno, Manuel; Oparina, Nina; Dozmorov, Mikhail G et al. (2018) Trans-Ethnic Mapping of BANK1 Identifies Two Independent SLE-Risk Linkage Groups Enriched for Co-Transcriptional Splicing Marks. Int J Mol Sci 19:|
|Koelsch, Kristi A; Cavett, Joshua; Smith, Kenneth et al. (2018) Evidence of Alternative Modes of B Cell Activation Involving Acquired Fab Regions of N-Glycosylation in Antibody-Secreting Cells Infiltrating the Labial Salivary Glands of Patients With Sjögren's Syndrome. Arthritis Rheumatol 70:1102-1113|
|LaBryer, Lauren; Sharma, Rohan; Chaudhari, Kaustubh Suresh et al. (2018) Kratom, an Emerging Drug of Abuse, Raises Prolactin and Causes Secondary Hypogonadism: Case Report. J Investig Med High Impact Case Rep 6:2324709618765022|
|Hinks, Anne; Marion, Miranda C; Cobb, Joanna et al. (2018) Brief Report: The Genetic Profile of Rheumatoid Factor-Positive Polyarticular Juvenile Idiopathic Arthritis Resembles That of Adult Rheumatoid Arthritis. Arthritis Rheumatol 70:957-962|
|Karp, David R; Chong, Benjamin F; James, Judith A et al. (2018) Mock Recruitment for the Study of Antimalarials in Incomplete Lupus Erythematosus Trial. Arthritis Care Res (Hoboken) :|
|Pelikan, Richard C; Kelly, Jennifer A; Fu, Yao et al. (2018) Enhancer histone-QTLs are enriched on autoimmune risk haplotypes and influence gene expression within chromatin networks. Nat Commun 9:2905|
|Patel, Zubin; Lu, Xiaoming; Miller, Daniel et al. (2018) A plausibly causal functional lupus-associated risk variant in the STAT1-STAT4 locus. Hum Mol Genet :|
|Kheir, Joseph M; Guthridge, Carla J; Johnston, Jonathon R et al. (2018) Unique clinical characteristics, autoantibodies and medication use in Native American patients with systemic lupus erythematosus. Lupus Sci Med 5:e000247|
|Young, K A; Munroe, M E; Harley, J B et al. (2018) Less than 7 hours of sleep per night is associated with transitioning to systemic lupus erythematosus. Lupus 27:1524-1531|
Showing the most recent 10 out of 284 publications